Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Enanta Pharmaceuticals (ENTA) Net Income towards Common Stockholders (2016 - 2025)

Historic Net Income towards Common Stockholders for Enanta Pharmaceuticals (ENTA) over the last 14 years, with Q3 2025 value amounting to -$18.6 million.

  • Enanta Pharmaceuticals' Net Income towards Common Stockholders rose 3507.51% to -$18.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$81.8 million, marking a year-over-year increase of 2941.25%. This contributed to the annual value of -$81.8 million for FY2025, which is 2941.25% up from last year.
  • Enanta Pharmaceuticals' Net Income towards Common Stockholders amounted to -$18.6 million in Q3 2025, which was up 3507.51% from -$18.3 million recorded in Q2 2025.
  • Enanta Pharmaceuticals' Net Income towards Common Stockholders' 5-year high stood at -$18.3 million during Q2 2025, with a 5-year trough of -$39.1 million in Q2 2023.
  • Its 5-year average for Net Income towards Common Stockholders is -$28.3 million, with a median of -$28.6 million in 2024.
  • As far as peak fluctuations go, Enanta Pharmaceuticals' Net Income towards Common Stockholders plummeted by 50391.34% in 2021, and later soared by 4199.92% in 2024.
  • Over the past 5 years, Enanta Pharmaceuticals' Net Income towards Common Stockholders (Quarter) stood at -$30.1 million in 2021, then rose by 3.75% to -$29.0 million in 2022, then dropped by 15.25% to -$33.4 million in 2023, then soared by 33.28% to -$22.3 million in 2024, then rose by 16.61% to -$18.6 million in 2025.
  • Its Net Income towards Common Stockholders was -$18.6 million in Q3 2025, compared to -$18.3 million in Q2 2025 and -$22.6 million in Q1 2025.